InvestLog
AVDL Avadel Pharmaceuticals plc logo

AVDL Avadel Pharmaceuticals plc

Healthcare
$21.64+0.00%ClosedMarket Cap: $2.12B

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

21.39

P/S

8.55

EV/EBITDA

205.49

DCF Value

$12.00

FCF Yield

1.7%

Div Yield

0.0%

Margins & Returns

Gross Margin

94.5%

Operating Margin

1.8%

Net Margin

-0.1%

ROE

-0.3%

ROA

-0.1%

ROIC

0.3%

Financials

View All
PeriodRevenueNet IncomeEPS
Q3 null$77.5M$20.0K$—
Q2 null$68.1M$9.7M$—
Q1 null$52.5M$-4.9M$—
Q4 null$50.4M$-5.0M$—

Analyst Ratings

View All

Consensus

Hold

Target (Consensus)

$21.43

Target (Median)

$20.00

Target Range

$18.50 - $30.00

0 Strong Buy0 Buy10 Hold0 Sell0 Strong Sell
Wells FargoEqual Weight
2025-11-20
UBSNeutral
2025-10-28
HC Wainwright & Co.Neutral
2025-10-23
Leerink PartnersMarket Perform
2025-10-23
JefferiesHold
2025-10-22

Trading Activity

Insider Trades

View All
Weiss Asset Management LPother: Former 10% Owner
SellWed Feb 18
Weiss Asset Management LP10 percent owner
SellWed Feb 18
Thornton Peter J.director
SellThu Feb 12
Thornton Peter J.director
SellThu Feb 12
Thornton Peter J.director
SellThu Feb 12

Company Info

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Country

IE

Exchange

—

Beta

1.31

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Peers

ALVO logoALVOANIP logoANIPBGM logoBGMEVO logoEVOGRDN logoGRDNMD logoMDOGN logoOGNPAHC logoPAHCQDEL logoQDELTLRY logoTLRY